Add news
March 2010
April 2010
May 2010June 2010July 2010
August 2010
September 2010October 2010
November 2010
December 2010
January 2011
February 2011March 2011April 2011May 2011June 2011July 2011August 2011September 2011October 2011November 2011December 2011January 2012February 2012March 2012April 2012May 2012June 2012July 2012August 2012September 2012October 2012November 2012December 2012January 2013February 2013March 2013April 2013May 2013June 2013July 2013August 2013September 2013October 2013November 2013December 2013January 2014February 2014March 2014April 2014May 2014June 2014July 2014August 2014September 2014October 2014November 2014December 2014January 2015February 2015March 2015April 2015May 2015June 2015July 2015August 2015September 2015October 2015November 2015December 2015January 2016February 2016March 2016April 2016May 2016June 2016July 2016August 2016September 2016October 2016November 2016December 2016January 2017February 2017March 2017April 2017May 2017June 2017July 2017August 2017September 2017October 2017November 2017December 2017January 2018February 2018March 2018April 2018May 2018June 2018July 2018August 2018September 2018October 2018November 2018December 2018January 2019February 2019March 2019April 2019May 2019June 2019July 2019August 2019September 2019October 2019November 2019December 2019January 2020February 2020March 2020April 2020May 2020June 2020July 2020August 2020September 2020October 2020November 2020December 2020January 2021February 2021March 2021April 2021May 2021
1234567
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
News Every Day |

FDA orders J&J contractor Emergent to stop vaccine production during inspection


Federal regulators told contract manufacturer Emergent BioSolutions last week to stop producing vaccine substance for Johnson & Johnson’s shot until officials finish inspecting a plant dogged by production mishaps.

The Food and Drug Administration on April 16 ordered Emergent to halt making the J&J vaccine's active ingredient and quarantine existing stock until agency staff complete an inspection and deliver their findings, according to an SEC filing Emergent released Monday. Federal inspectors began their assessment on April 12.

News of the FDA's order is the latest roadblock toward J&J's efforts to ramp up production of its vaccine — the only single-shot option available in the United States. The Biden administration says it has enough doses of vaccines from Moderna and Pfizer to vaccinate U.S. adults, but states and health care providers have said the J&J shot could be crucial to reach especially vulnerable or underserved populations, including the homeless, homebound seniors, prisoners and college students.

J&J enlisted Emergent early in the pandemic to help produce millions of doses of its vaccine, but the small contract manufacturer come under growing scrutiny from regulators — raising concerns about whether it can meet its production goals. Administration officials last month ordered another pharmaceutical giant, AstraZeneca, to leave the Maryland plant after Emergent mixed up ingredients for the two vaccines, ruining 15 million J&J doses.


"While we await the FDA's full feedback, we are working witih J&J and the FDA on strengthening the supply chain for this vitally important vaccine," Emergent said in a statement. "We acknowledge that there are improvements we must make to meet the high standards we have set for ourselves and to restore confidence in our quality systems and manufacturing processes."

The FDA declined to comment on the matter.

It is not clear how long Emergent’s production pause could last. While the FDA has not given Emergent emergency authorization to make J&J's shot — meaning none of the shots produced at the company's plant have been released to the public yet — the facility was expected to play a significant role in J&J’s production and hitting the promise of 100 million doses by June.

But production problems are not the only hurdle for the J&J vaccine. Nearly 7 million Americans received the single-dose shot before federal regulators last Tuesday advised providers nationwide to pause use over concerns over rare but serious blood clots. The pause could last weeks, further throwing into question how many J&J doses could be used by this summer.

The pharmaceutical company also enlisted Merck to help with filling and finishing vials and producing vaccine substance. But the facility that Merck intends to use for vaccine ingredients, in North Carolina, is not expected to begin manufacturing until the second half of this year.






Read also

What Venus moving into Gemini on May 8 means for YOUR sign

New Zealand weightlifter Laurel Hubbard on verge of becoming first transgender Olympian

Kushner company broke numerous laws by ripping off tenants: Judge's 252-page decision





News, articles, comments, with a minute-by-minute update, now on Today24.pro



Today24.pro — latest news 24/7. You can add your news instantly now — here
News Every Day

Aaron Rodgers Trade: Six Hypothetical Deals For Packers Quarterback